In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor
- 1 November 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (11), 4202-4204
- https://doi.org/10.1128/aac.00181-07
Abstract
The diarylquinoline R207910 is in clinical development for tuberculosis treatment. The MIC(50) for 41 drug-susceptible and 44 multidrug-resistant Mycobacterium tuberculosis clinical isolates was 0.032 microg/ml. Out of 20 additional mycobacterial species, three were found to be naturally resistant to R207910 and were shown to exhibit a polymorphism in their atpE genes.Keywords
This publication has 13 references indexed in Scilit:
- Diarylquinolines target subunit c of mycobacterial ATP synthaseNature Chemical Biology, 2007
- A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910Proteins-Structure Function and Bioinformatics, 2007
- Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in MycobacteriaAntimicrobial Agents and Chemotherapy, 2006
- Beijing/W GenotypeMycobacterium tuberculosisand Drug ResistanceEmerging Infectious Diseases, 2006
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisNature, 2000
- Species Identification of Mycobacteria Using rDNA SequencingPublished by Springer Nature ,1997
- Mycobacterium novocastrense sp. nov., a Rapidly Growing Photochromogenic MycobacteriumInternational Journal of Systematic and Evolutionary Microbiology, 1997
- Diagnosis and Treatment of Disease Caused by Nontuberculous MycobacteriaAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Cytomegalovirus: The Monster in the Closet?American Journal of Respiratory and Critical Care Medicine, 1997